Financial Statements 2018 – Re-audited under PCAOB standards

2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.

Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.

Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

Prometic reports its 2018 first quarter highlights and financial results